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The purpose of this thesis was to find an answer to the following problem:
does treatment with platelet function inhibiting drugs during cardiopul-
monary bypass (CPB) preserve platelet number and functionT
In the INTRODUCTION the way in which the coagulation system and the
platelets are activated during CPB is described. Heparin, which is routinely
given during CPB, inhibits act ivat ion of the coagulat ion system, but does
not prevent activation of the platelets. The platelets adhere to the synthetic
surfaces and ^ ggregate. Furthermore, general platelet aggregation is induced
by shear forces generated in the extracorporeal circuit. All of these factors
result in loss of platelet number and function and increase the bleeding
tendency after operation. The application of platelet function inhibiting
drugs during CPB is only useful if the inhibition is more or less complete, so
that the platelets are effectively preserved. The inhibition of platelet funcrion
should also be immediately reversible after CPB to obtain a normal hemo-
stasis postoperatively.
In CHAPTER 1, the platelet function inhibit ing drugs: Org 4122,Org4178,
sulf inpyrazone, dipyridamole, prostaglandin E, (PGEI) and prostacycl in
(PGIr) were tested in dogs without CPB for their capacity to inhibit  plateler
function and for the reversibi l i ty of this inhibit ion. PGE, and PGI, were the
most powerful and best reversible platelet function inhibiting drugs.
In CHAPTER 2, the platelet preserving capacities of PGE, and PGI, were
compared with a control group of dogs, during bubble oxygenator (BO) per-
fusion. Treatment with both drugs during CPB resulted in improved plateler
number and function thereafter. The post-operative bleeding times, pro-
longed in the controls, remained normal in the PGE, and PGI, treated
groups.
In CHAPTER 3, the variables are described which affect platelet number
and function in clinical circumstances and which could interfere with the
evaluation of platelet function inhibit ing drugs. This was studied in patients
undergoing coronary artery bypass graft ing with comparable perfusion
81
times. Platelets were better preserved in membrane oxygenator (MO)
perfusion when compared to BO perfusion. However, platelet function was
also affected by cardiotomy suction and by protamine administration. Pa-
tients perfused with the MO had statistically significantly less post-operative
blood loss and required fewer blood transfusions when compared to the
patients perfused with the BO.
In CHAPTER 4 rn a comparable group of patients, perfused with a MO, the
platelet preserving capacities of PGE, were tested. The hypotensive side-
effect of PGE, appeared to be so strong that only very small doses of PGE,
could be given. Treatment with this low dose did not result in preservation
of platelet number or function.
In CHAPTER 5, the hemodynamic side-effects of PGE, were quantitatively
described. Treatment with 50 nanogram of PGE, per kg per minute during
the whole period of CPB, was only possible when vasopressors were added,
but in most cases the PGE, dose had to be reduced and in some patients to be
stopped to maintain an acceptable perfusion pressure. Infusion of 50 nano-
gram of PGE, per kg per minute before CPB induced a fall in blood pressure
of 26 mm Hg. S7hen the same dose of PGE,, was given in a hemodynamical
stable period CPB, the mean arterial blood pressure dropped from74* 1l to
t7 + 10 mm Hg. The fall in blood pressure ranged from 0 to 50 mm Hg and
was dependent on the peripheral vascular resistance.
In the EPILOGUE a review is given of five studies published on PGI, treat-
ment during CPB in man. Treatment with PGI, did preserve platelet
number and function and decreased the post-operative blood loss. Flowever,
when taking into account our own hemodynamical studies of PGI, during
clinical CPB, we have to conclude that PGI, still has an unacceprable hypo-
tensive side-effect in CPB in man.
It can be stated that preservation of platelets during CPB can potentially be
obtained with platelet function inhibiting drugs like PGI', but that routine
application in open heart surgery will only be feasible if the vasodilarory
side-effects can be overcome.
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